

1 Chem. Pharm. Bull.

2 Regular Article

3

4 **Preparation and evaluation of newly developed chitosan salt coating**
5 **dispersions for colon delivery without requiring overcoating**

6

7 Kyohei Yamada^{1,#}, Yasunori Iwao^{1,#}, Ahmad Bani-Jaber², Shuji Noguchi¹,

8 Shigeru Itai^{1,*}

9

10

11 ¹*Graduate School of pharmaceutical sciences, University of Shizuoka, Shizuoka, Japan*

12 ²*Faculty of Pharmacy, The University of Jordan, Amman, Jordan*

13

14 ***#Both of these authors contributed equally to this work.***

15

16

17 *Address correspondence to: **Professor Shigeru Itai, Ph.D.**

18 *Department of Pharmaceutical Engineering, School of Pharmaceutical Sciences,*

19 *University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.*

20

Tel.: +81 54 264 5614; Fax: +81 54 264 5615;

21

E-mail: s-itai@u-shizuoka-ken.ac.jp.

22

23 **Summary**

24 Although chitosan (CS) has been recognized as one of good materials for
25 colon-specific drug delivery systems, an overcoating with an enteric coating polymer on the
26 surface of CS is absolutely necessary because CS is soluble in acidic conditions before
27 reaching colon. In the present study, to improve its stability towards acid, a newly
28 developed CS-laurate (CS-LA) material was evaluated as a coating dispersion for the
29 development of colon-specific drug delivery systems. Two types of CS such as CS250 and
30 CS600 which have different molecular weights were used to prepare CS-LA films by the
31 casting method. The CS250-LA films had smooth surfaces, whereas the surfaces of the
32 CS600-LA films were rough, indicating that the CS250-LA dispersion could form a denser
33 film than CS600-LA. Both of the CS-LA films maintained a constant shape over 22 h in a
34 pH 1.2 HCl/NaCl buffer, where the corresponding CS films rapidly disintegrated. In
35 addition, the CS250-LA film showed specific colon degradability in pH 6.0 phosphate
36 buffered solution containing 1.0% (w/v) β -glucosidase. As the results of tensile strength and
37 elongation at break, both CS-LA films were found to have flexible film properties. Finally,
38 the release of acetaminophen from disks coated with CS250-LA dispersions was
39 significantly suppressed in fluids at pH 1.2 and 6.8, whereas the disks coated with CS
40 solutions rapidly released drug in pH 1.2 fluids. Taken together, this study shows that LA
41 modification could be one of useful approaches to prepare CS films with acid stability and
42 colonic degradability properties without requiring overcoating.

43

44 **Keywords:** *Chitosan derivatives; acid stability; colonic delivery; coating dispersions; film.*

45

46 **Abbreviations:** 5-ASA, 5-aminosalicylic acid; CS, chitosan; LA, lauric acid; CS250,
47 medium molecular weight chitosan; CS600, high molecular weight chitosan; CS-LA,

48 chitosan-laurate; Tween 80, polyoxyethylene (20) sorbitan monooleate; FT-IR,
49 Fourier-transform infrared spectroscopy; SEM, scanning electron microscope; TS, tensile
50 strength; EB, elongation at break; APAP, acetaminophen.

51 1. Introduction

52 Interest in the design of oral, colon-specific drug delivery systems has increased
53 considerably during the last decade. ¹⁾ The possibility of being able to deliver drug
54 molecules directly to the diseased part of a colon, such as those parts affected by
55 inflammatory bowel diseases (IBD) and colon cancer, would mean that lower doses of the
56 drugs could be used to achieve therapeutic levels. Furthermore, the side effects typically
57 associated with the systemic absorption of drugs from the upper part of the gastrointestinal
58 tract could be reduced or even eliminated entirely by suppressing the release of the drug
59 until the delivery device enters the colon where a triggering mechanism initiates release.
60 Taken together with the fact that the number of IBD patients is currently increasing, ²⁾ there
61 is an obvious need for the development of an effective drug delivery system for the colon.

62 Numerous studies have already been conducted to develop drug delivery systems
63 for the colon. Among them, chitosan (CS) has attracted considerable attention as a good
64 material for the development of colon-specific drug delivery systems. ³⁾ CS is a natural
65 functional polymer containing 2-amino-2-deoxy-D-glucose and
66 2-acetamido-2-deoxy-D-glucose units, which are linked together through β -(1-4) bonds, ⁴⁾
67 and the glycosidic bonds making up the molecular chain in CS can be degraded by
68 β -glucosidases secreted from enteric bacteria. Numerous reports have appeared in the
69 literature pertaining to the formulation of CS capsules and tablets containing a variety of
70 different drugs. ^{5,6)} For example, Macleod et al. reported that tablets coated with a 3:1:1
71 (w/w/w) combination of pectin, hydroxypropyl methylcellulose polymers and CS remained
72 intact through the stomach and small intestine, and were then specifically disintegrated in
73 the human colon. ⁶⁾ Recently, a CS coating solution known as Chitocoat[®] was marketed as a
74 commercial product, and Furukawa et al. reported that tablets coated with Chitocoat
75 released only 10% of the total drug after they had been suspended in first fluid (JP15) for 2

76 h or second fluid for 3 h, whereas this Chitocoat coated tablet released 100% of the drug in
77 colonic fluid after 7 h. ⁷⁾ Furthermore, Furukawa et al. confirmed that the tablets were
78 specifically disintegrated in the colons of healthy adults by X-ray contrast radiography. ⁸⁾
79 However, since CS is itself dissolved under acidic conditions because of its amino groups
80 (at C-2), overcoating with an enteric coating polymer such as hydroxypropyl
81 methylcellulose phthalate is absolutely necessary to prevent these CS capsules and
82 CS-coated tablets from disintegrating under acidic conditions for colon-specific drug
83 delivery. This additional procedure increases not only the size of the final pharmaceutical
84 product, but also the level of complexity and overall cost of the manufacturing process. The
85 development of a new strategy to avoid the need for the overcoating of these CS
86 formulations is therefore a matter of significant concern.

87 One potential strategy to avoid the overcoating process involves the use of CS
88 derivatives whose amino groups (at C-2) have been modified to make them less susceptible
89 to acidic degradation. Several studies have been reported concerning the use of modified
90 CS derivatives, where the release of drug molecules from the corresponding formulations
91 could be suppressed in simulated gastric fluid. For example, Rekha and Sharma reported
92 that lauryl succinyl CS-nano/micro particles including insulin showed only 10% insulin
93 release from these particles when they were treated at pH 1.2 for 2 h, whereas approx. 75%
94 of insulin was released when native CS under the same conditions. ⁹⁾ In addition, we also
95 prepared the fatty acid salts of CS (CS-laurate and CS-palmitate) and evaluated the release
96 of ranitidine from matrices tablets containing these CS derivatives and the drug. ¹⁰⁾ The
97 results of this study revealed that the release of the drug was limited to approximately 30%
98 of the total drug after 2 h in 0.1 M HCl, whereas approximately 90% of the drug was
99 released from the corresponding control tablets containing unmodified CS. These results
100 therefore show that the modification of the amino groups (at C-2) of CS can be used as a

101 facile strategy to increase the acid stability of CS. However, as for the lauryl succinyl CS
102 described above, this material could only be prepared using methanol or
103 *N,N*-dimethylformamide,⁹⁾ which are classified as class II solvents in the Guideline for
104 Residual Solvents, and the removal of any residual solvent could therefore cause significant
105 operational issues during the manufacturing and formulation processes. In contrast, CS-LA
106 and CS-palmitate can be readily prepared without the need for harmful solvents. In addition,
107 both lauric acid (LA) and palmitic acid themselves are harmless to humans. Furthermore,
108 since the CS-LA tablets have been reported to show a high increase in water uptake
109 compared with CS-palmitate tablets,¹⁰⁾ CS-LA would be a suitable material for drug
110 delivery into the colon where little water exists.¹¹⁾ We recently reported that CS-LA also
111 showed a superior lubrication property in tableting process¹²⁾; however, there have been no
112 reports in the literature pertaining to the use of CS-LA in coating process.

113 With this in mind, the aim of this study was to prepare and evaluate novel CS-LA
114 coating dispersions that exhibited good stability under acidic conditions and specific
115 biodegradability in the colon for colon-specific drug delivery. In fact, we initially prepared
116 CS-LA dispersions and then prepared CS-LA films using a casting method. Two different
117 type of CS with median molecular weights 250 and 600 kDa were used in the current study
118 because it is well known that the characteristics of CS are dependent on their molecular
119 weight. Following a series of analytical experiments to determine the physicochemical
120 properties of films, the optimal dispersions were selected and sprayed directly onto the
121 surface of acetaminophen (APAP) disks to evaluate the drug release from the disks in
122 various testing fluids *in vitro*.

123

124

125

126 **2. Materials and methods**

127 **2.1. Materials**

128 Medium molecular weight CS (CS250) (190–310 kDa) and high molecular
129 weight CS (CS600) (600 kDa) with 75–85% deacetylation were purchased from Sigma
130 Aldrich (St. Louis, MO, USA). LA, glycerin and polyoxyethylene (20) sorbitan monooleate
131 (Tween 80) were purchased from Wako Pure Chemical Industries, Ltd (Osaka, Japan).
132 Chitocoat was provided as a gift from Freund Co., Ltd (Tokyo, Japan). β -Glucosidase from
133 almonds (β -glucosidase activity : 30 units/mg) was purchased from Tokyo Chemical
134 Industry Co., Ltd. (Tokyo, Japan). Distilled water was used in all of the experiment, and all
135 of the other chemicals and reagents used in the current study were purchased as the pure
136 laboratory grade.

137

138 **2.2. Preparation and physicochemical evaluation of CS-LA**

139 **2.2.1 Preparation of CS-LA**

140 An excess of CS250 and CS600 was added to acetic acid (0.15% w/v in water), and
141 the resulting mixture was stirred vigorously overnight. The excess solid CS was then removed
142 by centrifugation (Centrifuge 5430; Eppendorf, Hamburg, Germany) at 7830 rpm to give the
143 supernatant as a saturated CS solution. The concentrations of CS250 and CS600 in the
144 respective saturated solutions were found to be 8.68 ± 0.07 and 9.32 ± 0.10 mg/mL using a
145 drying method, respectively (**Table 1**). Sodium LA (1.5% w/w) was prepared by adding LA to
146 a 0.3% (w/v) solution of NaOH in water. Sodium LA (500 mL) was then added to 1000 mL of
147 each CS saturated solution, and the resulting mixtures were stirred vigorously for 1 h at room
148 temperature. Following a 2 h period of incubation, the mixtures were passed through a 420
149 μ m sieve to give the gelled CS-LA, which was washed with distilled water and dried at 55 °C
150 for 72 h. The resulting solid CS-LA samples were then milled on a TI-300 Samplemill (Heiko

151 Ltd, Tokyo, Japan) at 10,000 rpm followed by an FPS-1 edge mill (Terada seisakusho Ltd.,
152 Shizuoka, Japan). A large amount of ethanol, which is a good solvent for LA, was added to
153 the milled CS-LA materials, and the resulting suspensions were filtered to remove any
154 unreacted LA. This filtration process was repeated three times, and the resulting solid was
155 dried at 55 °C for 12 h to remove any residual solvent and then stored in a desiccator
156 overnight. The dried CS-LA material was then milled once again on the edge mill to give a
157 fine powder of CS-LA, which was passed through a 125 µm sieve before being used.

158

159 ***2.2.2. Measurement of the modification pattern of CS-LA using Fourier-transform*** 160 ***infrared spectroscopy (FT-IR)***

161 LA was ground into a fine powder using a mortar and pestle prior to analysis. The
162 FT-IR spectra of powdered samples of CS, LA and CS-LA were recorded on a DuraSample IR
163 II system (Shimadzu, Kyoto, Japan) at room temperature using an IRPrestige[®]-21 (Shimadzu).
164 The FT-IR spectra were recorded under the following conditions: apodization function,
165 Happ-Genzel; range of wavenumber, 500–4000 cm⁻¹; and the number of integration times, 20
166 times.

167

168 ***2.2.3. Measurement of modification ratio***

169 The modification ratio of LA to the amino groups of CS was measured using a
170 viscometer. The viscosity of the CS solution decreased as it reacted with LA to form CS-LA,
171 and this change was practically applied to determine the extent of the reaction.¹⁰⁾ An arbitrary
172 amount of 1.5% (w/v) sodium LA was added to a specific amount of the saturated CS solution
173 and the total amount of reaction solution was adjusted by adding an arbitrary amount of
174 distilled water. After the reaction, CS-LA was removed by centrifugation as mentioned above,
175 and the viscosity of supernatant was measured using a TVB-10M viscometer (Toki Sangyo

176 Co., Ltd., Tokyo, Japan). The modification ratio of LA to the amino groups of CS was
177 calculated from the concentration of sodium LA when the reduction in the viscosity reached
178 its lower limit. The molar concentration of amino groups on CS was calculated from the
179 average molecular weight per CS monomer. This calculation was based on the degree of
180 deacetylation of CS being 80%, because the degree of deacetylation of CS was reported to
181 75–85% by the supplier.

182

183 ***2.3. Preparation and physicochemical evaluation of CS-LA dispersion***

184 ***2.3.1. Preparation of CS solutions and CS-LA dispersions***

185 Acetic acid (0.3 g), Tween 80 (0.2 g) and glycerin (1.0, 2.0 or 3.0 g), which was
186 used as a plasticizer, were added to distilled water (160 mL), and the resulting mixture was
187 stirred with a spatula for 5 min. Two grams of CS or CS-LAs was then added to the solution,
188 and the resulting mixture was stirred with a spatula for 5 min. The mixture was then premixed
189 using a Speed Stabilizer (Kinematica, Luzern, Switzerland) at 20,000 rpm for 1 min before
190 being degassed on an ARE-250 planetary centrifugal mixer (Thinky Co., Tokyo, Japan) at
191 2,200 rpm for 1 min. The premixed suspension (5 mL) was then applied to a probe-sonicator
192 (Sonifier 250; Branson, Danbury, America) with its adjustable output control set at 6 for 5 min.
193 **Table 2** shows the formulation of the dispersion.

194

195 ***2.3.2. Measurement of the diameter of the dispersion***

196 The diameter of the CS-LA particles in dispersion was determined using a
197 Mastersizer2000 laser diffraction particle size analyzer (Marvern, Worcestershire, UK).
198 Ultrasonic treatment was not conducted during the evaluation process and the agitation speed
199 was at 1750 rpm. All of these measurements were performed in triplicate. Relative width of
200 particle size (R_w) was calculated by $(d_{90} - d_{10})/d_{50}$, where d_{10} , d_{50} , and d_{90} are 10%,

201 50%, and 90% of typical particle size distribution, respectively.

202

203 **2.4. Preparation and physicochemical evaluation of the polymer films**

204 **2.4.1. Preparation of the polymer films**

205 The polymer films were prepared using the casting method. The polymer dispersion
206 or Chitocoat was poured into a petri dish that had been covered with a Teflon seal (TZ-13;
207 Kawada Co., Tokyo, Japan). **Table 3** shows the formulation of Chitocoat. The thickness of the
208 films was adjusted to 100 μm . The films were subsequently cut into a range of different sizes
209 and used as samples.

210

211 **2.4.2. Surface observation of the polymer films**

212 The morphological characteristics of the surfaces of the films were evaluated by
213 scanning electron microscope (SEM) (JSM-5310LV; JEOL Ltd., Tokyo, Japan). Samples of
214 the films were cut into pieces, placed on double-sided adhesive tape and sputter-coated with
215 platinum under vacuum for 90 seconds prior to being visualized by SEM.

216

217 **2.4.3. Evaluation of the acid stability of the polymer films**

218 Disintegration tests were conducted using 1st fluid (pH 1.2) as a test fluid at $37 \pm$
219 0.5 °C according to the instruction provided by the Japanese Pharmacopoeia 16th edition
220 (JP16). All of the polymer films used in this test were 1 cm^2 in size.

221

222 **2.4.4. Evaluation of the biodegradability of polymer films in colon**

223 Polymer films (1 cm^2) were added to 10 mL of a phosphate buffered solution (pH
224 6.0) in a centrifuge tube (50 mL) both in the presence and absence of 1.0% (w/v)
225 β -glucosidase, and the resulting mixtures were agitated on a shaker (MMS-210; EYELA,

226 Tokyo, Japan) at 180 rpm for 24 h in an incubator (FMS-1000; EYELA, Tokyo, Japan) at
 227 37 °C.¹³⁾ The films were then washed with distilled water and dried at 55 °C. The weight loss
 228 of the films was then calculated using the following equation (Eq. (1)):

$$229 \quad W_{\text{loss}} = \frac{W_i - W_f}{W_i} \times 100 \quad (1)$$

230 Where W_{loss} is the weight loss of the films after 24 h, W_i is the initial weight of the films and
 231 W_f is the final weight of the films after 24 h.

232

233 **2.4.5. Evaluation of the mechanical properties of the polymer films**

234 A strip of film (1 cm × 4 cm) was fixed at either end to the attachments of a
 235 Tensilon precision universal tester (Orientec, Tokyo, Japan), and the film was then pulled
 236 apart at a rate of 10 mm/min until it broke. The load (N) and elongation (mm) values at the
 237 point that the film broke were detected, and the tensile strength (TS) and elongation at break
 238 (EB) were calculated using the experimental data according to Eqs. (2) and (3), respectively,
 239 as follows:

$$240 \quad \text{TS (MPa)} = \frac{\text{Tensile load (N)}}{\text{Rupture area (mm}^2\text{)}} \quad (2)$$

$$241 \quad \text{EB (\%/mm}^2\text{)} = \frac{\text{Elongation (mm)}}{\text{Initial length (mm)}} \times \frac{100 (\%)}{\text{Rupture area (mm}^2\text{)}} \quad (3)$$

242 Where rupture area indicates the area of the fracture surface. In this study, the rupture area
 243 was simply regarded as a vertical section of the film, and the TS and EB values were therefore
 244 calculated using a rupture area of 100 × film thickness (mm) because all of the films were 1
 245 cm in width.

246

247 **2. 5. Drug dissolution test from disks coated with CS and the CS-LA polymer**

248 Disks coated with the dispersion were prepared to evaluate the rate of drug release

249 through the film coatings.

250

251 **2.5.1. Preparation of the disks**

252 APAP tablets (300 mg, diameter; 13 mm) were prepared using a hydraulic single
253 punch tableting machine at 100 MPa. The disks were prepared by embedding the tablets into
254 polyvinyl chloride pipes (inner diameter 1.33 cm; height 0.7 cm) and using coins and
255 aluminum foil to cover the reverse side of disks.

256

257 **2.5.2. Preparation of the coating disks**

258 A spray nozzle was fixed 2.5 cm above the disk, and a small amount of Chitocoat
259 or CS250-LA dispersion containing 1.0% (w/w) glycerin was sprayed onto the surface of the
260 disk at 0.75 MPa of spray pressure. The resulting disk was then thoroughly dried using a hair
261 dryer. These operations were repeated until the amount of weight gained by the disk after
262 drying reached 28 mg.

263

264 **2.5.3. Dissolution test**

265 The dissolution of APAP from the coated disks was examined using the paddle
266 method listed in JP16. The test solution was composed of 900 mL of hydrochloride buffer (pH
267 1.2) or phosphate buffered solution (pH 6.8) at 37 ± 0.5 °C and a paddle rotation speed of 50
268 rpm. Samples were removed from the mixture at 5.0, 10, 15, 20, 25, 30, 45, 60, 75, 90, 105
269 and 120 min. The absorbance values of the samples at 243 nm were determined using a
270 UV-mini spectrophotometer (Shimadzu), and the APAP concentrations were calculated based
271 on the absorbance value of a standard solution.

272

273 **2.6. Statistics**

274 Statistical analyses were performed using the Student *t*-test. A probability value of *p*
275 < 0.05 was considered to indicate statistical significance.

276

277

278 3. Results and discussion

279 3.1. Characterization of CS-LA

280 **Figure 1** shows the FT-IR spectra of CS, LA and CS-LA, where the letters A and B
281 have been used to indicate materials based on CS250 and CS600, respectively. All of these
282 spectra contained a typical band in the region of 2850–2930 cm⁻¹, which was attributed to a
283 C–H stretching vibration. This particular peak was more prominent in the CS-LA material
284 than it was in CS. Also, the peak around 1650 cm⁻¹ corresponding to a C=O stretching
285 vibration was not observed in CS-LA. Furthermore, the presence of two peaks in the region
286 1550–1650 cm⁻¹ was consistent with the presence of an ion pair between the amino and
287 carboxyl groups. These characteristics were observed in two the different types of CS and
288 CS-LA regardless of their molecular weight, which indicated that the amino groups of CS had
289 formed an ion pair with the carboxyl groups of LA (**Fig. 2**). The modification ratios of LA to
290 the amino groups of CS250 and CS600 were determined 56.6±3.5 and 68.7±3.5%,
291 respectively by measuring the viscosity (**Table 1**).

292

293 3.2. Particle size of dispersion

294 **Table 4** shows the particle size and relative width of particle size (R_w) of the
295 CS-LA dispersion. When CS was used as a control to prepare dispersions, it was dissolved in
296 acetic acid and the dispersion became solution. The CS250-LA dispersion showed a smaller
297 mean particle size ($20 \pm 1 \mu\text{m}$) than that of the CS600-LA dispersion ($92 \pm 15 \mu\text{m}$), which was
298 attributed to the lower molecular weight CS250 as well as lower modification ratio of

299 CS250-LA.

300

301 **3.3. Characterization of the polymer films**

302 **3.3.1 Surface morphology of the polymer films**

303 Consideration of the SEM images revealed that the surface of the CS600-LA film
304 was rough, whereas the surface of the CS250-LA films was smooth (**Fig. 3**). This difference
305 in the surface morphology of the two films was attributed to the smaller mean particle size of
306 the CS250-LA dispersion. The surface morphology of the polymer films appeared to be
307 independent of the concentration of glycerin, because changes the concentration of glycerin
308 had no discernible effect on the surface morphology of the polymer films. In contrast to the
309 CS-LA films, the CS films showed a smooth surface, which was attributed to the CS materials
310 being in solution.

311

312 **3.3.2 Acid stability of polymer films**

313 **Figure 4** shows the results of the disintegration tests for the different films in 1st
314 fluid (pH 1.2). The CS250 films prepared using dispersions containing 0.5, 1.0 and 1.5%
315 glycerin disintegrated in 10.3, 16.0 and 17.7 h, respectively (**Fig. 4A, closed bar**). The CS600
316 films prepared using dispersions containing 0.5, 1.0 and 1.5% glycerin disintegrated in 9.0,
317 14.0 and 17.0 h, respectively (**Fig. 4B, closed bar**). The fact that the CS films prepared using
318 dispersions containing 1.5% glycerin could maintain their form for 17 h was attributed to the
319 thick nature of the films (about 100 μm). In contrast, CS250-LA films prepared using
320 dispersions containing 0.5, 1.0 and 1.5% glycerin showed longer disintegration times of 22.0,
321 39.3 and 42.3 h, respectively (**Fig. 4A, open bar**). CS600-LA films prepared using
322 dispersions containing 0.5, 1.0 and 1.5% glycerin also showed longer disintegration times of
323 47.0, 59.0 and 62.7 h, respectively (**Fig. 4B, open bar**). These results demonstrated that the

324 disintegration times of the CS-LA films were more than twice as long as those of the CS films.
325 Based on these results, it was obvious that the derivatization of CS led to greater stability
326 under gastric condition. In fact, even though the coating thickness of these formulations was
327 only a few micrometers, these data suggested that formulations coated with an appropriately
328 thick layer of CS-LA could pass through the stomach without releasing their drug. Also, an
329 increase in the glycerin concentration led to an increase in the disintegration time in the acidic
330 test fluid. This result could be attributed to an increase in the plasticization effect of glycerin,
331 which enhances the flexibility of the film and provides it with greater acidic stability.

332

333 *3.3.3 Degradation of the polymer films*

334 **Figure 5** shows the weight loss details of the polymer films in phosphate buffered
335 solution (pH 6.0) both in the presence and absence of β -glucosidase after 24 h. Although all of
336 the CS250 films were disintegrated to some extent in the absence of β -glucosidase (**Fig. 5A,**
337 **closed bar**), they all completely disintegrated in the presence of β -glucosidase (**Fig. 5A, open**
338 **bar**). The CS600 films were also disintegrated to some extent in the absence β -glucosidase
339 (**Fig. 5B**). However, a significant weight loss was only observed for the CS600 films
340 containing 0.5% glycerin in the presence of β -glucosidase (**Fig. 5B**). It has been reported that
341 lower molecular weight CS is more easily degraded than higher molecular weight CS.¹⁴⁾ As
342 for CS-LA films, all of the CS250-LA films showed high weight losses in the presence of
343 β -glucosidase regardless of their glycerin concentration (i.e., 84.8, 90.5 and 84.9% with 0.5,
344 1.0 and 1.5% glycerin, respectively) (**Fig. 5C, open bar**), whereas the weight losses in the
345 absence of β -glucosidase were much lower (i.e., 20.9, 39.0 and 49.4% with 0.5, 1.0 and 1.5%
346 glycerin, respectively) (**Fig. 5C, closed bar**). In contrast, only the CS600-LA containing 0.5%
347 glycerin showed a significant weight loss (**Fig.5D**). This result was attributed to the
348 CS250-LA material being more easily recognized by the β -glucosidase than CS600-LA

349 because the modification ratio of the amino groups on CS250-LA was lower ($56.6\pm 3.5\%$) than
350 that of CS600-LA ($68.7\pm 3.5\%$) (**Table 1**). However, given that CS can be broken down in a
351 number of different ways in the colon by a number of different enzymes, it is envisaged that
352 the CS-LA coating film would be degraded to a greater extent *in vivo*.

353

354 **3.3.4 Mechanical properties of polymer films**

355 **Figure 6** shows the TS and EB results for the of the polymer films. The black dot
356 lines in these graphs indicate the measured values for the Chitocoat film as a control. The CS
357 and CS-LA films displayed very similar tendencies in terms of their TS and EB values.
358 Although the EB values appeared to be independent of the glycerin concentration, the TS
359 values decreased with increasing glycerin concentration, which indicated that the CS and
360 CS-LA films could be made more flexible depending on their glycerin concentration. A
361 similar tendency was also observed as the molecular weight of the CS increased, which
362 indicated that the both films could be made more flexible depending on the molecular weight
363 of the CS material. These results therefore showed quite clearly that CS-LA dispersions
364 containing more than 1.0% (w/w) glycerin could be used to form a coating film with suitable
365 flexibility properties, because the films showed mechanical properties (i.e., TS about 0.7
366 MPa; EB about $13\%/mm^2$) almost equal to those of Chitocoat films.

367

368 **3.4 Dissolution test using disks**

369 The results provided above for the evaluation of the polymer films suggested that
370 CS250-LA dispersions containing more than 1.0% (w/w) glycerin could be used to make
371 films with suitable acid stability, colonic degradability and flexible film properties. With this
372 in mind, we proceeded to evaluate the actual ability of this CS250-LA dispersion containing
373 1.0% (w/w) glycerin to suppress the release of a drug from a disk coated in a film of

374 CS250-LA. **Figure 7** shows the results of a dissolution test using coating disks. In a test fluid
375 at pH 1.2, disks coated in Chitocoat released drug more rapidly than the other disks. This
376 result was attributed to the Chitocoat films not working effectively as coating films because
377 they disintegrated under the acidic conditions. **Table 5** shows the drug permeation rates from
378 the disks, which were calculated from the slopes of lines. In the test fluid at pH 1.2, the values
379 for the Chitocoat and CS250-LA disks were 7148 and 195 mg/h/cm² · μm, respectively. This
380 37-fold difference in the results effectively highlights the increase in the acid stability of CS
381 resulting from the derivatization process. This result therefore shows quite clearly that the
382 release of the drug in the stomach can be sufficiently suppressed using the CS250-LA coating
383 dispersion. Furthermore, the drug permeation rates of the Chitocoat and CS250-LA disks in a
384 test fluid at pH 6.8 were 390 and 195 mg/h/cm² μm, respectively. The value for the Chitocoat
385 disks was therefore 2-fold larger than that of the CS250-LA disks. This difference was
386 attributed to an increase in the hydrophobicity of the CS derivative following its modification
387 with LA, which led to a reduction in the permeation of the drug to the buffer. These results
388 suggest that CS250-LA coating films could better suppress the release of drug molecules from
389 formulations in the small intestine than Chitocoat films, and that CS250-LA coating films
390 could therefore be used to effectively deliver drugs to the colon.

391

392

393 **4. Conclusions**

394 CS250-LA dispersions containing more than 1.0% (w/w) glycerin gave coating
395 films with acid stability, colonic degradability and flexible properties suitable for the delivery
396 of drug molecules to the colon. The release of APAP from disks coated with CS250-LA
397 dispersions containing 1.0% (w/w) glycerin was significantly suppressed in test fluids at pH
398 values of 1.2 and 6.8, which suggested that drugs could be effectively delivered to the colon

399 by coating this dispersion onto formulations without requiring overcoating. Based on the
400 results of this study, further *in vivo* work using IBD model mice should be needed to evaluate
401 the usefulness of this dispersion for the coating of tablets or granules containing
402 5-aminosalicylic acid (5-ASA) to achieve colon- specific drug delivery in comparison to
403 commercially available 5-ASA products.

404

405

406 **Acknowledgments**

407 The authors would like to express their sincere thanks to Freund Co., Ltd and
408 Iwaki Seiyaku Co., Ltd for kindly providing the reagents required for this study.

409

410 **References**

- 411 1). Omwancha, W.S., Mallipeddi, R., Valle, B.L., Neau, S.H., 2012. *Int. J.*
412 *Pharm.*, **441**, 343–351.
- 413 2). Ribeiro, L.N.M., Alcântara, A.C.S., Darder, M., Aranda, P., Araújo-Moreira,
414 F.M., Ruiz-Hitzky, E., 2013. *Int. J. Pharm.*, **463**, 1–9.
- 415 3). Bernkop-Schnürch, A., Dünnhaupt, S., 2012. *Eur. J. Pharm. Biopharm.*, **81**,
416 463–469.
- 417 4). Rinaudo, M., 2006. *Prog. Polym. Sci.*, **31**, 603–632.
- 418 5). Tozaki, H., Komoike, J., Tada, C., Maruyama, T., Terabe, A., Suzuki, T.,
419 Yamamoto, A., Muranishi, S., 1997. *J. Pharm. Sci.*, **86**, No. 9, 1016–1021.
- 420 6). Macleod, G.S., Fell, J.T., Collet, J.H., Sharma, H.L., Smith, A.M., 1999. *Int.*
421 *J. Pharm.*, **187**, 251–257.
- 422 7). Furukawa, K., Imamura, N., Yamanaka, K., Takei, N., Mizobata, K., Gotoh,
423 Y., Itoh, K., 2010. *Pharm. Tech. Japan*, **26**, 71–74.
- 424 8). Furukawa, K., Imamura, N., Yamanaka, K., Takei, N., Mizobata, K., Gotoh,
425 Y., Itoh, K., Kamimura, M., 2009. *Pharm. Tech. Japan*, **25**, 63–66.
- 426 9). Rekha, M.R., Sharma, C.P., 2009. *J. Controlled Release*, **135**, 144–151.
- 427 10). Bani-Jaber, A., Hamban, I., Alkawareek, M., 2011. *Arch. Pharm. Res.*, **35**,
428 1159–1168.
- 429 11). Sako, K., Nakashima, H., Sawada, T., Fukui, M., 1996. *Pharm. Res.*, **13**,
430 594–598.
- 431 12). Bani-Jaber, A., Kobayashi, A., Yamada, K., Haj-Ali, D., Uchimoto, T., Iwao,
432 Y., Noguchi, S., Itai, S., 2015. *Int. J. Pharm.*, **483**, 49–56.

433 13). He, W., Fan, L.F., Xiang, B., Li, C.L., Du, Q., Chang, Y.Z., Cao, D.Y., 2009.

434 *Eur. J. Pharm. Biopharm.*, **72**, 266–274.

435 14). Zhang, H., Neau, S.H., 2001. *Biomaterials*, **23**, 2761–2766.

436

437 **Table 1. Physicochemical properties of CS-LA.**

	Molecular weight of CS (kDa)	Solubility of CS in 0.15% (w/v) acetic acid (mg/mL)	Modification ratio of CS-LA (%)
CS250-LA	190–310	8.68±0.07	56.6±3.5*
CS600-LA	600	9.32±0.10	68.7±3.5

438 Solubility of CS represents the mean ± S. D. (n=3). *, $p < 0.05$, compared with
439 CS600-LA.

440

441 **Table 2. Composition of the CS solution and CS-LA dispersions.**

Composition	Ratio (% , w/w)
CS or CS-LA	1.0
Glycerin	0.5, 1.0, 1.5
Tween 80	0.1
Acetic acid	0.15
Distilled water	Adjust to 100

442

443 **Table 3. Composition of Chitocoat.**

Composition	Ratio (% ,w/w)
CS	2.0
Glycerol esters of fatty acids	1.0
Glycerin	1.0
Acetic acid	0.6
Distilled water	95.4

444

445

446 **Table 4. Particle size and relative width of particle size (R_w) properties of each CS-LA**
 447 **dispersion.**

	d_{10} (μm)	d_{50} (μm)	d_{90} (μm)	R_w
CS250-LA	6.1 \pm 3.3	20 \pm 1	53 \pm 12	2.3 \pm 0.8
CS600-LA	21 \pm 5	92 \pm 15	222 \pm 29	2.2 \pm 0.3

448 Each value represents the mean \pm S.D. ($n=3$).

449

450 **Table 5. Permeation rates of APAP from the Chitocoat and CS250-LA coated disks.**

	Permeation rate ($\text{mg/h/cm}^2 \cdot (\mu\text{m})$)	
	pH1.2	pH6.8
Chitocoat	7148 \pm 4465	390 \pm 70
CS250-LA	195 \pm 92*	195 \pm 136

451 *, $p < 0.05$, compared with Chitocoat coated disks.

452

453 **Figure captions**

454 **Figure 1. FT-IR spectra of CS, LA and CS-LA.** Figures represent (A) CS250 and (B)
455 CS600.

456

457 **Figure 2. Chemical structure of CS-LA.**

458

459 **Figure 3. Scanning electron microscope images of the surfaces of the CS and CS-LA**
460 **films.**

461

462 **Figure 4. Disintegration times of the CS and CS-LA films in 1st fluid for the**
463 **disintegration test (pH 1.2). (A) CS250 and (B) CS600.** Each column represents the mean \pm
464 S.D. ($n=3$). *, $p < 0.05$ and **, $p < 0.01$, compared with each CS film.

465

466 **Figure 5. Weight loss of the (A) CS250 film, (B) CS600 film, (C) CS250-LA film and**
467 **CS600-LA film in pH 6.0 phosphate buffer both with and without 1.0 % (w/v)**
468 **β -glucosidase after 24 h.** Each column represents the mean \pm S.D. ($n=3$). *, $p < 0.05$ and **,
469 $p < 0.01$, compared with each film in the absence of β -glucosidase.

470

471 **Figure 6. Tensile strength and Elongation at break values of the (A) CS film and (B)**
472 **CS-LA film.** Black dot lines demonstrate the measured values of Chitocoat. Each column
473 represents the mean \pm S.D. ($n=3$).

474

475 **Figure 7. APAP release behavior from Chitocoat and CS250-LA dispersion coated disks**
476 **in test fluids at pH 1.2 and pH 6.8.** Each symbol represents the mean \pm S.D. ($n=3$).

477

Fig. 1






Fig. 2




479

Fig. 3



480

Fig. 4



481

482

483


484

485

486

487

Fig. 5




488

489


490

Fig. 6

A. CS film



B. CS-LA film



491

492

Fig. 7

